Current Research Studies

A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

AZALEA - A Phase 3 Study of Nipocalimab in Pregnancies at Risk for Severe HDFN

  • Condition(s): Other
  • Phase: III
  • Clinicaltrials.gov ID: NCT05912517

What is the goal of the study?

A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: